COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PD-1/PD-L1 Pathway Study on Septic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01161745
Recruitment Status : Completed
First Posted : July 14, 2010
Last Update Posted : July 14, 2010
National Natural Science Foundation of China
Information provided by:
Changhai Hospital

Brief Summary:
The investigators want to identify that whether PD-1/PD-L1 pathway will change in human sepsis, and whether PD-1/PD-L1 pathway play an important role in sepsis induced immunosuppression.

Condition or disease

Detailed Description:

First, we will detect PD-L1 expression on PBMC of septic patients and healthy controls.

Second, blockade of PD-1/PD-L1 pathway in vitro and stimulate with some biomolecules and then analyze the PBMC function and apoptosis by flow cytometry.

Then, compare with healthy controls and find the differences.

Layout table for study information
Study Type : Observational
Actual Enrollment : 39 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: PD-1/PD-L1 Pathway in T Lymphocyte Apoptosis and Monocyte Dysfunction in Septic Patients
Study Start Date : December 2008
Actual Primary Completion Date : February 2010
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Biospecimen Retention:   Samples Without DNA
peripheral venous blood from septic patients and healthy controls, anticoagulate with EDTA-K2

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
patients who develop sepsis

Inclusion Criteria:

  • patients who develop sepsis

Exclusion Criteria:

  • patients with cirrhosis or renal dysfunction
  • patients with dyscrasia
  • patients with autoimmunity diseases
  • patients with severe cardiac and pulmonary diseases
  • patients with hematological diseases
  • patients with diabetes mellitus
  • patients with malignant tumors

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01161745

Sponsors and Collaborators
Changhai Hospital
National Natural Science Foundation of China
Layout table for investigator information
Principal Investigator: Xiao-ming Deng, doctor Changhai Hospital, the Second Military Medical University
Layout table for additonal information
Responsible Party: Xiao-ming Deng, Department of Anesthesiology and Intensive Care Unit Identifier: NCT01161745    
Other Study ID Numbers: ANETHDEPT-001
First Posted: July 14, 2010    Key Record Dates
Last Update Posted: July 14, 2010
Last Verified: June 2010
Keywords provided by Changhai Hospital:
Additional relevant MeSH terms:
Layout table for MeSH terms
Systemic Inflammatory Response Syndrome
Pathologic Processes